ELU001

DRUG2 trials

Conditions

AML, ChildhoodAcute Myeloid LeukemiaEndometrial AdenocarcinomaEndometrial CancerEndometrial Cancer RecurrentEndometrial CarcinosarcomaEndometrial Clear Cell AdenocarcinomaEndometrial Diseases

Phase 1

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

TerminatedNCT05001282

Elucida OncologyEndometrial Adenocarcinoma, Endometrial Cancer, Endometrial Cancer Recurrent +22

Start: 2021-09-13End: 2024-06-07Updated: 2024-08-07

ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML

WithdrawnNCT05622591

Elucida OncologyAcute Myeloid Leukemia, AML, Childhood, Refractory Pediatric AML +1

Start: 2024-06-07End: 2024-06-07Updated: 2024-08-07

Journal of Clinical Oncology2024-06-013 citations

Phase 1 trial of a novel C’Dot drug conjugate (CDC), ELU001, in patients with solid tumors known to overexpress folate receptor alpha (FRα).

Journal of Clinical Oncology2023-06-017 citations

Abstract CT255: ELU-FRα-1: a study to evaluate ELU001 in patients with solid tumors that overexpress folate receptor alpha (FRα)

Cancer Research2023-04-146 citations

Abstract 1075: Therapeutic targeting of CBFA2T3-GLIS2 infant AML with ELU001 - folate receptor alpha-directed C’Dot-drug-conjugate

Cancer Research2022-06-152 citations

Abstract 1077: Stability and safety evaluation of ELU001, a targeted C’Dot drug conjugate for the potential treatment of folate receptor alpha-overexpressing cancers

Cancer Research2022-06-151 citations

ELU-FRα-1: A study to evaluate ELU001 in patients with solid tumors that overexpress folate receptor alpha (FRα).

Journal of Clinical Oncology2022-06-015 citations

ELU001

Sponsors

Conditions

Phase 1

Related Papers